BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients
Version of Record online: 25 NOV 2011
© 2011 The Authors. APMIS © 2011 APMIS
Volume 120, Issue 5, pages 380–386, May 2012
How to Cite
PELTTARI, H., SCHALIN-JÄNTTI, C., AROLA, J., LÖYTTYNIEMI, E., KNUUTILA, S. and VÄLIMÄKI, M. J. (2012), BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS, 120: 380–386. doi: 10.1111/j.1600-0463.2011.02844.x
- Issue online: 19 APR 2012
- Version of Record online: 25 NOV 2011
- Received 25 October 2011. Accepted 26 October 2011
- low-risk thyroid carcinoma;
- BRAF mutation;
Pelttari H, Schalin-Jäntti C, Arola J, Löyttyniemi E, Knuutila S, Välimäki MJ. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS 2012; 120: 380–6.
The BRAF V600E mutation may serve as a marker of disease recurrence in well-differentiated papillary thyroid cancer (PTC). Our aim was to study if TNM stage I or II PTC patients, with and without recurrence after long-term follow-up would differ in BRAF status. BRAF status was retrospectively determined in tumour tissue from a cohort of low-risk PTC patients (n = 461) with and without recurrence after 16 years of follow-up. Initial treatment was total thyroidectomy (TTE) and radioiodine remnant ablation (RRA). Forty-six patients (9.9%) experienced disease recurrence. BRAF mutation was positive in 66% (17/26) of patients with and 68% (17/25) without recurrence (p = NS). Fifty per cent of BRAF positive and 53% of BRAF negative patients experienced disease recurrence (p = NS). Time to recurrence was 52 (range 18–144) and 36 (range 16–71) months, respectively (p = NS). Primary tumour size, nodal metastasis and local infiltration at presentation did not differ between BRAF positive and negative patients (2.0 vs 2.2 cm, 21% vs 35% and 6% vs 12%, respectively, all p = NS). Taken together, BRAF V600E is common in Finnish patients with low-risk PTC but does not predict recurrence after long-term follow-up after initial treatment with TTE and RRA.